YiChang HEC ChangJiang Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
YiChang HEC ChangJiang PharmaceuticalDie Erträge des Sektors -33.7% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Pharmaceuticals growing auf 6.1% pro Jahr stiegen. Die Einnahmen waren declining mit einer durchschnittlichen Rate von 3.2% pro Jahr. YiChang HEC ChangJiang Pharmaceutical Die Eigenkapitalrendite des Unternehmens beträgt 15.6%, und die Nettomargen liegen bei 20.1%.
Key information
-15.7%
Earnings growth rate
-15.2%
EPS growth rate
Pharmaceuticals Industry Growth | 5.6% |
Revenue growth rate | 2.7% |
Return on equity | 23.4% |
Net Margin | 31.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30Revenue & Expenses BreakdownBeta
How YiChang HEC ChangJiang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 6,295 | 1,993 | 1,939 | 192 |
30 Sep 23 | 5,978 | 1,566 | 1,870 | 190 |
30 Jun 23 | 5,661 | 1,139 | 1,801 | 187 |
31 Mar 23 | 4,703 | 608 | 1,676 | 158 |
31 Dec 22 | 3,745 | 77 | 1,551 | 130 |
30 Sep 22 | 2,875 | -18 | 1,324 | 115 |
30 Jun 22 | 2,005 | -113 | 1,097 | 101 |
31 Mar 22 | 1,459 | -351 | 990 | 105 |
31 Dec 21 | 914 | -588 | 883 | 110 |
30 Sep 21 | 690 | -436 | 986 | 98 |
30 Jun 21 | 467 | -285 | 1,089 | 87 |
31 Mar 21 | 1,407 | 277 | 1,278 | 90 |
31 Dec 20 | 2,348 | 839 | 1,468 | 92 |
30 Sep 20 | 3,792 | 1,204 | 1,933 | 74 |
30 Jun 20 | 5,236 | 1,568 | 2,399 | 55 |
31 Mar 20 | 5,730 | 1,743 | 2,634 | 27 |
31 Dec 19 | 6,224 | 1,919 | 2,869 | 0 |
30 Sep 19 | 5,162 | 1,598 | 2,356 | 0 |
30 Jun 19 | 4,099 | 1,276 | 1,843 | 0 |
31 Mar 19 | 3,305 | 1,109 | 1,441 | 0 |
31 Dec 18 | 2,510 | 943 | 1,038 | 0 |
30 Sep 18 | 2,466 | 961 | 968 | 0 |
30 Jun 18 | 2,422 | 980 | 897 | 0 |
31 Mar 18 | 2,012 | 813 | 731 | 0 |
31 Dec 17 | 1,602 | 647 | 565 | 0 |
30 Sep 17 | 1,325 | 557 | 443 | 0 |
30 Jun 17 | 1,048 | 467 | 322 | 0 |
31 Mar 17 | 995 | 424 | 318 | 0 |
31 Dec 16 | 942 | 381 | 314 | 0 |
30 Sep 16 | 904 | 354 | 294 | 0 |
30 Jun 16 | 866 | 327 | 274 | 0 |
31 Mar 16 | 779 | 297 | 236 | 0 |
31 Dec 15 | 693 | 266 | 197 | 0 |
30 Sep 15 | 637 | 236 | 190 | 0 |
30 Jun 15 | 581 | 207 | 183 | 0 |
31 Mar 15 | 511 | 171 | 177 | 0 |
31 Dec 14 | 441 | 135 | 170 | 0 |
31 Dec 13 | 316 | 58 | 141 | 0 |
Qualität der Erträge: 1558 hat eine große einmalige gain von CN¥9.5B, die sich auf die Finanzergebnisse der letzten 12 Monate auf 31st December, 2023 auswirkt.
Wachsende Gewinnspanne: 1558Die aktuellen Gewinnspannen (31.7%) sind höher als im letzten Jahr (2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Ergebnisentwicklung: 1558Die Erträge des Unternehmens sind in den letzten 5 Jahren um 33.7% pro Jahr zurückgegangen.
Beschleunigtes Wachstum: 1558Das Gewinnwachstum des Unternehmens im letzten Jahr (2501.2%) übertrifft seinen 5-Jahres-Durchschnitt (-15.7% pro Jahr).
Erträge im Vergleich zur Industrie: 1558 Das Gewinnwachstum im vergangenen Jahr (2501.2%) übertraf das der Branche Pharmaceuticals 15.4% .
Return on Equity
Hohe Eigenkapitalrendite: 1558Die Eigenkapitalrendite des Unternehmens (23.4%) wird als hoch angesehen.